%0 Journal Article %1 Petersen2001 %A Petersen, M. C. %A Palmer, F. B. %D 2001 %J Ment Retard Dev Disabil Res Rev %K Botulinum Toxin Type A; Cerebral Palsy; Clinical Trials; Female; Humans; Infant, Newborn; Magnesium Sulfate; Male; Muscle Spasticity; Pregnancy; Pregnancy, Multiple; Rhizotomy; Risk Factors; Treatment Outcome %N 1 %P 30--37 %R 3.0.CO;2-2 %T Advances in prevention and treatment of cerebral palsy. %U http://dx.doi.org/3.0.CO;2-2 %V 7 %X In recent years there have been a number of advances in understanding of predisposing and protective factors in the development of cerebral palsy in infants. Multiple gestation births, maternal infection, and maternal and fetal thrombophilic conditions all predispose to the development of CP in the infant. Opportunities for prevention of CP may develop from an improved understanding of these factors and their mechanisms of operation. Similar progress has been made in the evaluation of treatments for CP and the effects of these treatments on the individual's impairment, function, and disability. Selective posterior rhizotomy and Botulinum toxin A are now widely used in the treatment of spasticity. The challenge remains to determine how effectively these promising interventions can alter long-term function and quality of life outcomes in children and adults with CP.

@article{Petersen2001, abstract = {In recent years there have been a number of advances in understanding of predisposing and protective factors in the development of cerebral palsy in infants. Multiple gestation births, maternal infection, and maternal and fetal thrombophilic conditions all predispose to the development of CP in the infant. Opportunities for prevention of CP may develop from an improved understanding of these factors and their mechanisms of operation. Similar progress has been made in the evaluation of treatments for CP and the effects of these treatments on the individual's impairment, function, and disability. Selective posterior rhizotomy and Botulinum toxin A are now widely used in the treatment of spasticity. The challenge remains to determine how effectively these promising interventions can alter long-term function and quality of life outcomes in children and adults with CP.}, added-at = {2014-07-19T21:00:40.000+0200}, author = {Petersen, M. C. and Palmer, F. B.}, biburl = {https://www.bibsonomy.org/bibtex/2a9e6b4703ff86138d670ab74ba49d838/ar0berts}, doi = {3.0.CO;2-2}, groups = {public}, interhash = {897c312a430d57e3daddd36579c1f88e}, intrahash = {a9e6b4703ff86138d670ab74ba49d838}, journal = {Ment Retard Dev Disabil Res Rev}, keywords = {Botulinum Toxin Type A; Cerebral Palsy; Clinical Trials; Female; Humans; Infant, Newborn; Magnesium Sulfate; Male; Muscle Spasticity; Pregnancy; Pregnancy, Multiple; Rhizotomy; Risk Factors; Treatment Outcome}, number = 1, pages = {30--37}, pii = {3.0.CO;2-2}, pmid = {11241880}, timestamp = {2014-07-19T21:00:40.000+0200}, title = {Advances in prevention and treatment of cerebral palsy.}, url = {http://dx.doi.org/3.0.CO;2-2}, username = {ar0berts}, volume = 7, year = 2001 }